Pharminent

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

Merck’s CETP inhibitor anacetrapib and Novartis’ monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category. http://www.mmm-online.com/pipeline/merck-novartis-pipeline-stunners-headline-surprisingly-good-month-for-cv-agents/article/671717/

Filed under: Cardiovascular